Parallel Advisors’s Albireo Pharma Inc ALBO Stock Holding History

Parallel Advisors’s Portfolio ALBO Stock Details ALBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-9	Closed	–	–	3625
2022 Q2	$0	Buy	+9	New	+$237	﹤0.01%	3488

Other funds holding ALBO

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Parallel Advisors's ALBO Position: Q3 2022 in Review

Parallel Advisors sold out of Albireo Pharma Inc (ALBO) in Q3 2022, closing a stake of 9 shares.

Parallel Advisors first reported a position in ALBO in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 108 funds tracked by Wall St. Rank hold ALBO as of Q3 2022.

Parallel Advisors reported no remaining Albireo Pharma Inc position as of Q3 2022 after selling out during the quarter.
Parallel Advisors sold 9 Albireo Pharma Inc shares in Q3 2022.
Parallel Advisors first reported a position in Albireo Pharma Inc in Q2 2022 and held it in 1 quarter.
Parallel Advisors's Albireo Pharma Inc position peaked at $0 in Q2 2022.
108 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q3 2022.

Based on Parallel Advisors's 13F filing for Q3 2022, filed 10 Nov 2022.